NovoCure (NVCR) Non-Current Assets (2014 - 2026)
NovoCure (NVCR) posted Non-Current Assets of $156.7 million for Q2 2026, little changed sequentially from $156.3 million in Q1 2026, and down 3.63% YoY from $162.6 million in Q2 2025.
NovoCure (NVCR) Non-Current Assets (2014 - 2026) Analysis & Trends
NovoCure has reported Non-Current Assets for 13 years, with the latest figure at $156.7 million in Q2 2026.
- Quarterly Non-Current Assets fell 3.63% year-over-year to $156.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $156.7 million (down 3.63% YoY) and the FY2025 annual result came in at $157.6 million, up 17.43% from the prior year.
- Non-Current Assets was little changed at $156.7 million in Q2 2026 per NVCR's latest filing, from $156.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $162.6 million in Q2 2025 and troughed at $68.1 million in Q2 2022.
- A 5-year average of $118.4 million and a median of $119.0 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 39.64% in 2022, then decreased 3.63% in 2026.
- Over 5 years, Non-Current Assets stood at $80.1 million in 2022, then jumped by 39.44% to $111.7 million in 2023, then grew by 20.13% to $134.2 million in 2024, then climbed by 17.43% to $157.6 million in 2025, then decreased by 0.59% to $156.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $156.7 million, $156.3 million, and $157.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 84.70 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 33.51 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 68.24 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 37.24 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 7.05 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 2.37 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 26.75 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 20.19 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 8.29 Bn |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn | 156.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 156.67 Mn |
| Mar 31, 2026 | 156.26 Mn |
| Dec 31, 2025 | 157.60 Mn |
| Sep 30, 2025 | 161.34 Mn |
| Jun 30, 2025 | 162.58 Mn |
| Mar 31, 2025 | 159.51 Mn |
| Dec 31, 2024 | 134.21 Mn |
| Sep 30, 2024 | 126.72 Mn |
| Jun 30, 2024 | 119.33 Mn |
| Mar 31, 2024 | 118.72 Mn |
| Dec 31, 2023 | 111.72 Mn |
| Sep 30, 2023 | 98.35 Mn |
| Jun 30, 2023 | 93.53 Mn |
| Mar 31, 2023 | 85.35 Mn |
| Dec 31, 2022 | 80.12 Mn |
| Sep 30, 2022 | 71.84 Mn |
| Jun 30, 2022 | 68.12 Mn |
| Mar 31, 2022 | 69.63 Mn |
| Dec 31, 2021 | 65.97 Mn |
| Sep 30, 2021 | 51.45 Mn |